Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Hemorrhagic complications with prasugrel therapy for vascular neurointerventional procedures.

Leslie-Mazwi TM, Chandra RV, Yoo AJ, Rabinov JD, Hirsch JA.

J Neurointerv Surg. 2013 Jul;5(4):344-5. doi: 10.1136/neurintsurg-2012-010406. Epub 2012 Jun 7. No abstract available.

PMID:
22679132
2.

Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures.

Akbari SH, Reynolds MR, Kadkhodayan Y, Cross DT 3rd, Moran CJ.

J Neurointerv Surg. 2013 Jul;5(4):337-43. doi: 10.1136/neurintsurg-2012-010334. Epub 2012 May 3.

3.

Prasugrel is effective and safe for neurointerventional procedures.

Stetler WR, Chaudhary N, Thompson BG, Gemmete JJ, Maher CO, Pandey AS.

J Neurointerv Surg. 2013 Jul;5(4):332-6. doi: 10.1136/neurintsurg-2012-010302. Epub 2012 May 22.

PMID:
22619468
4.

[The ACCOAST study].

De Servi S, Menozzi A, De Luca L.

G Ital Cardiol (Rome). 2014 May;15(5):276-82. doi: 10.1714/1563.17019. Italian. No abstract available.

PMID:
25002165
5.

Switching from ticagrelor to prasugrel: a warning.

Parodi G, Bellandi B, Antoniucci D.

Int J Cardiol. 2014 Oct 20;176(3):1089-90. doi: 10.1016/j.ijcard.2014.07.123. Epub 2014 Aug 1. No abstract available.

PMID:
25125013
6.

Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).

Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK.

Am J Cardiol. 2014 Jan 1;113(1):64-9. doi: 10.1016/j.amjcard.2013.09.019. Epub 2013 Oct 3.

PMID:
24169009
7.

P2Y12 inhibition in patients with NSTEMI--can later be better?

Keaney JF Jr.

N Engl J Med. 2013 Sep 12;369(11):1056-7. doi: 10.1056/NEJMe1308820. Epub 2013 Sep 1. No abstract available.

8.

Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.

Deharo P, Bassez C, Bonnet G, Pankert M, Quilici J, Lambert M, Verdier V, Morange P, Alessi MC, Bonnet JL, Cuisset T.

Int J Cardiol. 2013 Dec 10;170(2):e21-2. doi: 10.1016/j.ijcard.2013.10.043. Epub 2013 Oct 14. No abstract available.

PMID:
24231059
9.

[Prasugrel--oral (Efient)].

[No authors listed]

J Pharm Belg. 2010 Dec;(4):131-2. French. No abstract available.

PMID:
21298816
10.

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.

Sherwood MW, Wiviott SD, Peng SA, Roe MT, Delemos J, Peterson ED, Wang TY.

J Am Heart Assoc. 2014 Apr 14;3(2):e000849. doi: 10.1161/JAHA.114.000849.

11.

Switching from clopidogrel to prasugrel in patients having coronary stent implantation.

Parodi G, De Luca G, Bellandi B, Comito V, Valenti R, Marcucci R, Carrabba N, Migliorini A, Ramazzotti RN, Gensini GF, Abbate R, Antoniucci D.

J Thromb Thrombolysis. 2014 Oct;38(3):395-401.

PMID:
24659131
12.

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.

J Am Coll Cardiol. 2014 Mar 25;63(11):1061-70. doi: 10.1016/j.jacc.2013.12.023. Epub 2014 Jan 30.

13.

Desensitization to prasugrel: cardiology's increased need for allergy consultation.

Mutnick JL.

Ann Allergy Asthma Immunol. 2012 Feb;108(2):124-5. doi: 10.1016/j.anai.2011.11.005. Epub 2011 Dec 3. No abstract available.

PMID:
22289733
14.

Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.

Orban M, Byrne RA, Hausleiter J, Laugwitz KL, Sibbing D.

Thromb Haemost. 2011 Sep;106(3):555-8. doi: 10.1160/TH11-04-0267. Epub 2011 Jul 4. No abstract available.

PMID:
21725582
15.

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators..

N Engl J Med. 2013 Sep 12;369(11):999-1010. doi: 10.1056/NEJMoa1308075. Epub 2013 Sep 1.

17.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators..

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
18.

Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.

Clemmensen P, Dridi NP, Holmvang L.

Cardiovasc Drugs Ther. 2013 Jun;27(3):239-45. doi: 10.1007/s10557-013-6444-2. Review.

PMID:
23380983
19.

Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.

De Luca G, Verdoia M, Schaffer A, Suryapranata H, Parodi G, Antoniucci D, Marino P.

J Thromb Thrombolysis. 2014 Oct;38(3):388-94.

PMID:
24659130
20.

Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.

Ferreiro JL, Ueno M, Tello-Montoliu A, Tomasello SD, Seecheran N, Desai B, Rollini F, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2013 Feb;6(2):182-4. doi: 10.1016/j.jcin.2012.10.007. No abstract available.

Supplemental Content

Support Center